Research Analysts Set Expectations for INBX FY2026 Earnings

Inhibrx Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright lowered its FY2026 loss forecast for Inhibrx Biosciences to $9.22 per share from $8.93, while maintaining a Buy rating and a $220 price target. The current-year consensus forecast is a loss of $9.91 per share.
  • Analyst opinion is mixed but leans positive: MarketBeat reports a Moderate Buy consensus and an average price target of $185, based on ratings ranging from Strong Buy to Sell.
  • Inhibrx’s latest quarter slightly missed EPS expectations, reporting a $2.46-per-share loss versus the $2.45 expected; revenue of $2.0 million topped estimates of $1.9 million.
  • MarketBeat previews the top five stocks to own by December 1st.

Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings estimates for shares of Inhibrx Biosciences in a research report issued on Monday, November 16th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($9.22) per share for the year, down from their previous forecast of ($8.93). HC Wainwright currently has a "Buy" rating and a $220.00 target price on the stock. The consensus estimate for Inhibrx Biosciences' current full-year earnings is ($9.91) per share. HC Wainwright also issued estimates for Inhibrx Biosciences' Q4 2026 earnings at ($2.27) EPS, Q1 2027 earnings at ($2.23) EPS, Q2 2027 earnings at ($2.18) EPS, Q3 2027 earnings at ($1.94) EPS, Q4 2027 earnings at ($1.72) EPS and FY2027 earnings at ($8.02) EPS.

INBX has been the subject of a number of other reports. Citigroup reaffirmed a "market perform" rating on shares of Inhibrx Biosciences in a research note on Friday, September 18th. Wall Street Zen downgraded Inhibrx Biosciences from a "hold" rating to a "strong sell" rating in a report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inhibrx Biosciences in a research report on Friday, September 11th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Inhibrx Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $185.00.

Get Our Latest Stock Analysis on INBX

Inhibrx Biosciences Stock Performance

Shares of NASDAQ INBX opened at $74.18 on Wednesday. The business's 50-day moving average price is $93.60 and its two-hundred day moving average price is $92.17. Inhibrx Biosciences has a one year low of $57.30 and a one year high of $155.29.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its quarterly earnings results on Friday, November 13th. The company reported ($2.46) earnings per share for the quarter, missing analysts' consensus estimates of ($2.45) by ($0.01). The firm had revenue of $2.00 million for the quarter, compared to analyst estimates of $1.90 million.

Insider Buying and Selling

In related news, Director Jon Kayyem acquired 5,000 shares of the business's stock in a transaction that occurred on Tuesday, September 8th. The shares were acquired at an average cost of $113.52 per share, with a total value of $567,600.00. Following the purchase, the director owned 424,360 shares of the company's stock, valued at approximately $48,173,347.20. The trade was a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Douglas Forsyth bought 2,500 shares of Inhibrx Biosciences stock in a transaction that occurred on Tuesday, September 8th. The stock was bought at an average price of $114.65 per share, with a total value of $286,625.00. Following the completion of the acquisition, the director owned 227,064 shares in the company, valued at approximately $26,032,887.60. The trade was a 1.11% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 62,540 shares of company stock worth $6,347,507 and sold 1,500 shares worth $168,590. Insiders own 18.26% of the company's stock.

Institutional Trading of Inhibrx Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC increased its stake in shares of Inhibrx Biosciences by 380.3% in the third quarter. Sterling Capital Management LLC now owns 293 shares of the company's stock worth $29,000 after purchasing an additional 232 shares during the period. Integrated Wealth Concepts LLC acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth about $31,000. Quantbot Technologies LP acquired a new position in shares of Inhibrx Biosciences during the 2nd quarter worth about $68,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Inhibrx Biosciences during the 3rd quarter worth about $75,000. Finally, State of Wyoming bought a new stake in Inhibrx Biosciences during the 2nd quarter valued at approximately $116,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

About Inhibrx Biosciences

(Get Free Report)

Inhibrx Biosciences, Inc. is a U.S.-based biopharmaceutical company focused on developing biologic medicines for cancer and other serious diseases. Its research uses protein engineering to create investigational therapies designed to engage specific targets in the body. The company's oncology pipeline has included INBRX-109, an antibody designed to activate the DR5 receptor and studied for chondrosarcoma, and INBRX-106, an investigational OX40-targeting antibody. These candidates are experimental and are not approved medicines.

Featured Articles

Earnings History and Estimates for Inhibrx Biosciences (NASDAQ:INBX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Inhibrx Biosciences Right Now?

Before you consider Inhibrx Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.

While Inhibrx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines